WellDoc, LifeScan join forces on digital diabetes partnership

The collaboration is aimed at improving care management for people with type 2 diabetes. 

By Suzanne Elvidge • Sept. 14, 2016

Allergan beefs up R&D with Vitae buy

The specialty pharma continues its bolt-on acquisition strategy, adding the dermatology-focused Vitae for $639 million. 

By Lisa LaMotta • Sept. 14, 2016

Catalent picks up Pharmatek, expanding West Coast reach

The CMO announced another acquisition, adding to its spray-dry capabilities and its geographic reach. 

By Lisa LaMotta • Sept. 13, 2016

Takeda terminates MacroGenics DART deal early

Despite Takeda realigning its priorities, MacroGeneics remains optimistic about further partnering. 

By Suzanne Elvidge • Sept. 13, 2016

GSK continues sell-off of non-core assets

The British pharma sold its anesthesia business for nearly $375 million.

By Lisa LaMotta • Sept. 12, 2016

Horizon adds rare disease drugs in $800M Raptor deal

The Irish specialty pharma will pay a small premium for Raptor, which markets Procysbi and Quinsair. 

By Ned Pagliarulo • Sept. 12, 2016

Sanofi, Verily launch Onduo for diabetes care

The big pharma teamed up with the Google subsidiary to launch a diabetes joint venture. 

By Lisa LaMotta • Sept. 12, 2016

Gilead comments on split rumors

Revenues from the big biotech's hepatitis C franchise have declined sharply, leading some to speculate the company could be worth more split in two. 

By Ned Pagliarulo • Sept. 8, 2016

Allergan picks up gene therapy company

Acquisition of RetroSense Therapeutics further builds out the Irish pharma's eye care portfolio. 

By Lisa LaMotta • Sept. 6, 2016

Expanding pipeline, Amgen picks up multiple myeloma med

The California biotech acquired global rights to an early-stage bispecific antibody from Boehringer Ingelheim. 

By Suzanne Elvidge • Sept. 2, 2016

Sunovion snaps up Cynapsus in $624M deal

Cynapsus' lead candidate treats a common side effect experienced by patients with Parkinson's disease. 

By Ned Pagliarulo • Sept. 1, 2016

Medivir plans year-end split

The Swedish biotech will separate into two companies which will focus separately on commercial and R&D operations.

By Lisa LaMotta • Aug. 31, 2016

Mallinckrodt sharpens specialty pharma focus

IBA Molecular will pay $690 million to acquire Mallinckrodt's nuclear imaging business, which is mostly centered on the U.S. market. 

By Ned Pagliarulo • Aug. 26, 2016

Cyon licenses PCSK9 inhibitor from Novartis

The biotech is taking over development of big pharma drug as a treatment for sepsis, not cholesterol-lowering. 

By Kirell Lakhman • Aug. 24, 2016

BioCardia finds alternative funding solution

The California biotech is conducting a reverse merger to help fund a late-stage study. 

By Lisa LaMotta • Aug. 24, 2016

Pfizer continues dealmaking with antibiotics buy

The pharma giant will pay as much as $1.6 billion for AstraZeneca's small-molecule anti-infectives portfolio. 

By Ned Pagliarulo • Aug. 24, 2016

DS Biopharma creates fibrotic spin out

The privately held biotech is creating a new company to focus on fibrotic diseases. 

By Lisa LaMotta • Aug. 23, 2016

Pfizer wins Medivation with $14B bid

The big pharma adds to its cancer portfolio with a highly sought-after acquisition. 

By Lisa LaMotta • Aug. 22, 2016

Roche, Eleven Bio eye the ocular market

The pair team up on the biotech's IL-6 antagonist in a deal worth $270 million. 

By Nicole Gray • Aug. 19, 2016

Bayer, CRISPR christen Casebia

The big pharma and the biotech reveal the details of the joint venture they established late last year. 

By Lisa LaMotta • Aug. 19, 2016

FDA expedites Aspen's prostate drug ahead of merger

The newly merged company will provide women's health, men's health and OTC products. 

By Nicole Gray • Aug. 18, 2016

Trek Therapeutics in-licenses Medivir hep C drug

 The agreement includes development and commercialization and has a global purview, with the exception of China, Taiwan, Hong Kong and Macai.

By Nicole Gray • Aug. 18, 2016

Rasna Therapeutics taps public market with merger

The new company will trade on NASDAQ-OTC under the ticker ATVM.

By Nicole Gray • Aug. 18, 2016

Tioma lands $86M Series A for immunotherapy

Formerly known as Vasculox, the biotech pulled in a large funding round to support its CD47 checkpoint inhibitor program. 

By Lisa LaMotta • Aug. 16, 2016

Mallinckrodt plans regen med acquisition

The UK specialty pharma has entered into a merger agreement with a privately-held regenerative medicine company. 

By Nicole Gray • Aug. 12, 2016